New York: So Many Targets, So Little Time
This is part 3 of our 5-part series on the Drug Discovery for Neurodegenerative Disease conference.
6400 RESULTS
Sort By:
This is part 3 of our 5-part series on the Drug Discovery for Neurodegenerative Disease conference.
Peter Lorre’s Joel Cairo in <em>The Maltese Falcon</em> might have gotten it right with his gardenia-scented business card...
Alzheimer disease brings on a tendency to wander, and patients sometimes become disoriented even in the most familiar surroundings...
This is part 2 of our 5-part series on the Drug Discovery for Neurodegenerative Disease conference.
This is part 1 of our 5-part series on the Drug Discovery for Neurodegenerative Disease conference.
Synapses, those miniscule gaps across which neurons signal one another, are far from static...
Myriad genetics presented additional 24-month data from the completed follow-on study of a phase 2 trial of its experimental Alzheimer drug...
Boosting neuronal excitation with acetylcholinesterase inhibitors is one way of tackling cognitive decline in Alzheimer disease...
Two papers last week addressed related puzzles in Huntington’s and related diseases, that is, why...
Synaptic plasticity is a contest between long-term potentiation (LTP) and long-term depression (LTD), with the...
Pat McCaffrey Interviews Randy Buckner
Congratulations are in order for this year’s winners of the MetLife Foundation Award for Medical Research in Alzheimer’s Disease...
The current issue of Neuron contains a scientific debate that bears watching...
In the 15 February Neuron, Masafumi Ihara and Makoto Kinoshita at Kyoto University in Japan reveal not one, but two critical...
As any marketing guru will tell you, getting your message to the right audience is essential if you want your business to thrive...